MedTech Atlas
Back to medical device regulatory guideAll countries
Middle East & AfricaENPublic regulatory overview

United Arab Emirates (UAE)

Market Overview Population: Approximately 10 million (2024); approximately 90% are expatriate residents, with UAE nationals accounting for approximately 10%; the population is high...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAStrong benefit

FDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingPartial / emerging acceptance

NMPA is an emerging reference factor here: it may be accepted or considered for selected products, documents, or review discussions, but the scope must be verified before filing.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: United Arab Emirates (UAE)
  • Product line: Medical devices
  • Regulator / source: Federal regulator and registration services - Emirates Drug Establishment (EDE), MOHAP - Define medical equipment registration, importation, and federal compliance entry points; verify whether the service has migrated to EDE
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Market Size: Medical device market valued at approximately USD 3 billion in 2023 — the second-largest market in the GCC after Saudi Arabia; a high-income market with per capita healthcare expenditure among the highest globally
  • Local requirement: UAE medical device entry should be separated into four layers: federal product registration / EDE-MOHAP service ownership, local representative / importer, Dubai / Abu Dhabi hospital access, and regional hub / re-export structure. A registration certificate is only the entry condition; commercial execution usually depends on the local licence holder, hospital-access team, service capability, and regional inventory model.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Market Overview

  • Population: Approximately 10 million (2024); approximately 90% are expatriate residents, with UAE nationals accounting for approximately 10%; the population is highly concentrated in Dubai and Abu Dhabi
  • Healthcare System: A dual-track system — a government-led public healthcare system (MOH public hospitals, Abu Dhabi's SEHA hospital network, Dubai's DHA hospital network) operating alongside a thriving private healthcare sector; private hospitals account for approximately 45% of the market, the highest proportion of private healthcare among the GCC countries
  • Market Size: Medical device market valued at approximately USD 3 billion in 2023 — the second-largest market in the GCC after Saudi Arabia; a high-income market with per capita healthcare expenditure among the highest globally
  • Market Characteristics: A population dominated by expatriates (from 180+ countries) drives high acceptance of internationally standardized medical devices; medical tourism is flourishing — Dubai Healthcare City (DHCC) is the most important medical tourism and healthcare business hub in the Middle East; multiple free trade zones (Dubai Healthcare City, JAFZA, etc.) attract international medical device companies to establish regional headquarters and distribution bases
  • Procurement Characteristics: High acceptance of premium and innovative medical devices; private hospital procurement decisions are relatively flexible; public hospital procurement is affected by government budget cycles; international brand certifications (CE/FDA) are important technical scoring criteria in procurement evaluations
  • Strategic Position: The UAE (especially Dubai) is the commercial hub for the entire Middle East and Africa (MENA/MEA) region; many multinational medical device companies establish their Middle East regional headquarters in Dubai, serving Saudi Arabia, Qatar, Kuwait, Egypt, Africa, and surrounding markets

Market-Entry Logic

UAE medical device entry should be separated into four layers: federal product registration / EDE-MOHAP service ownership, local representative / importer, Dubai / Abu Dhabi hospital access, and regional hub / re-export structure. A registration certificate is only the entry condition; commercial execution usually depends on the local licence holder, hospital-access team, service capability, and regional inventory model.

Layer Market-entry meaning Operating focus
Federal product registration Medical equipment registration, importation, and trading services are in a MOHAP-to-Emirates Drug Establishment (EDE) service-transition period Verify the latest e-service portal, service owner, account holder, and certificate-holder requirements before starting
Local representative / importer Foreign manufacturers generally need a UAE licensed establishment / local representative to execute registration, importation, customs clearance, and trade fulfilment Contracts should define account control, certificate ownership, import permits, variations, termination, and handover obligations
Dubai / Abu Dhabi hospital access Dubai Health / DHA, Department of Health Abu Dhabi, SEHA / PureHealth, and private hospital groups shape procurement access and clinical-use pathways Product registration alone is not enough; prepare vendor onboarding, clinical evidence, pricing, and service plans in parallel
Free zones and regional distribution Dubai Healthcare City, JAFZA, Dubai Science Park, and similar zones support regional headquarters, warehousing, re-export, and distributor management UAE can operate as a GCC / MENA hub, but re-export does not automatically create Saudi, Egyptian, or other national registrations
Service and engineering capability Imaging, IVD, surgical systems, ICU / OR equipment, and installed devices depend heavily on installation, calibration, maintenance, and training Assess the distributor's engineer coverage, spare-parts inventory, SLA, and target-hospital relationships

For foreign manufacturers, the best sequence is usually to confirm the EDE / MOHAP product-registration route and local licence holder first, then appoint a commercial partner that can access Dubai / Abu Dhabi priority hospital networks, while using the UAE as a regional demonstration, training, and distribution hub rather than treating it as a single registration-only market.

Main Players and Channel Map

Player type Representative institutions / companies Commercial meaning
Federal regulator and registration services Emirates Drug Establishment (EDE), MOHAP Define medical equipment registration, importation, and federal compliance entry points; verify whether the service has migrated to EDE
Emirate-level healthcare systems Dubai Health / DHA, Department of Health Abu Dhabi, SEHA / PureHealth, Dubai Healthcare City Shape Dubai / Abu Dhabi hospital access, facility licensing, procurement, and clinical-use ecosystem
Medical device distributors / supply-chain companies Gulf Drug, Al Hayat Pharmaceuticals, MPC Healthcare, and similar groups Cover pharmaceuticals, devices, consumables, diagnostics, and hospital supply chains; common entry channel for foreign brands
Private hospital groups Mediclinic Middle East, NMC Healthcare, Aster DM Healthcare, Saudi German Health UAE, Cleveland Clinic Abu Dhabi, and others Often adopt premium equipment, specialty consumables, digital health, and innovative devices faster than public procurement
Regional hubs and free zones Dubai Healthcare City, JAFZA, Dubai Science Park, Dubai CommerCity, and others Suitable for regional headquarters, training centres, spare-parts depots, demonstration centres, and MENA distribution control
Multinational device local teams Siemens Healthineers, GE HealthCare, Philips, Medtronic, Abbott, BD, Roche Diagnostics, and others Maintain UAE regional teams or partner networks to support brand presence, clinical education, after-sales service, and key-account management

Channel due diligence should verify three points: whether the representative can genuinely perform medical equipment registration and importation; whether it can access the target hospital groups and government procurement channels; and whether it has enough engineers, spare parts, and clinical-application support. The UAE is small but premium, and a price-only distributor is usually insufficient for high-value devices.

  1. EDE transition is reshaping the registration entry point: Healthcare-product regulation is moving from the traditional MOHAP route toward the Emirates Drug Establishment service system. Companies should rely on the latest official e-service pages and leave room in contracts and project plans for portal changes, account migration, and file-format changes.
  2. Regional hub value continues to grow: The UAE's domestic population is limited, but Dubai and Abu Dhabi's regional headquarters, medical tourism, exhibition, and re-export roles make the country a MENA / MEA commercialization hub for devices.
  3. Private healthcare and high-end specialties support premium devices: Medical tourism, private hospital expansion, cardiovascular care, oncology, orthopedics, imaging, IVD, and minimally invasive surgery support growth in high-end equipment and consumables.
  4. After-sales service is becoming a market-access threshold: Public and private hospitals increasingly value uptime, training, clinical-application support, and local repair response. Distributors without engineering capability will limit installed-equipment scale-up.
  5. Digital health, AI, and software devices matter more: Dubai and Abu Dhabi invest heavily in digital health, telemedicine, AI-assisted diagnosis, and hospital digitization. SaMD, cybersecurity, data compliance, and clinical validation will become more common access issues.
  6. Registration and commercial channels must be designed separately: The UAE can serve as a regional showcase, but each target country still needs an independent compliance route. When using UAE registration and distributor networks to expand across GCC / MENA, build country-by-country plans for registration, pricing, importation, and service.

Regulatory Authorities — Three Parallel Systems (Core Understanding)

The UAE is a federal state, and medical device / healthcare-product market entry requires understanding both federal product registration / EDE-MOHAP service ownership and emirate-level healthcare access. Product registration, importation, healthcare-facility procurement, hospital access, and clinical use rules can be influenced by different layers. The following three systems are best treated as an operating map for "product registration + healthcare-facility access + procurement ecosystem", not as identical product-registration substitutes.

System 1: MOHAP (Federal Level)

  • Full Name: Ministry of Health and Prevention
  • Jurisdiction: Federal level, covering the five smaller emirates outside Dubai and Abu Dhabi (Sharjah, Ajman, Umm Al Quwain, Fujairah, Ras Al Khaimah); additionally, a MOHAP registration certificate carries basic validity nationwide
  • Online System: MOHAP eServices (https://mohap.gov.ae)
  • Key Regulations: Federal Law No. 4 of 1983 (on pharmaceuticals and medical devices) and subsequent amendments; MOHAP Medical Devices Regulation

System 2: DHA (Dubai Emirate Level)

  • Full Name: Dubai Health Authority
  • Jurisdiction: The Emirate of Dubai (including all Dubai healthcare institutions: Dubai Healthcare City, Jumeirah, Deira, etc.)
  • Online System: DHA Sheryan System (https://sheryan.dha.gov.ae)
  • Key Characteristics: Dubai is the UAE's largest private healthcare market; DHA registration is a prerequisite for entering the Dubai healthcare market; healthcare institutions within Dubai Healthcare City (DHCC) must comply with DHA regulations

System 3: DOH (Abu Dhabi Emirate Level)

  • Full Name: Department of Health Abu Dhabi (formerly HAAD)
  • Jurisdiction: The Emirate of Abu Dhabi (including Abu Dhabi city, Al Ain, Al Dhafra, and other Abu Dhabi areas)
  • Online System: DOH ShafaMIS System (https://www.doh.gov.ae)
  • Key Characteristics: Abu Dhabi is the UAE's political capital with the largest public healthcare system (SEHA hospital network); DOH has significant influence over procurement of high-end specialist equipment

Practical Guidance

Covering the full UAE market typically requires: MOHAP + DHA + DOH — three separate registrations, or selective registration based on the target sales region (e.g., for Dubai market only, prioritize DHA; for the five smaller emirates only, MOHAP is sufficient). The three systems have highly similar registration requirements but differ in details, and documents must be adapted for each.

Device Classification System

Local Class Risk Level EU Equivalent FDA Equivalent Description
Class A Lowest risk Class I Class I Non-invasive, low-contact devices; simple single-use consumables
Class B Low-medium risk Class IIa Class II (partial) Short-term invasive devices, routine diagnostic equipment, surgical instruments, etc.
Class C Medium-high risk Class IIb Class II–III Long-term non-cardiovascular implants, high-energy therapy devices
Class D Highest risk Class III Class III/PMA Cardiovascular implants, neural devices, devices incorporating animal-derived materials

Note: The classification rules of all three systems (MOHAP, DHA, DOH) are essentially consistent, all referencing the international GHTF/IMDRF classification framework. Product classification must be confirmed with the target registration authority before the registration application; the three systems may have subtle differences in classification determinations for borderline products.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.